@entity6 -related changes in @entity9484 -induced release of striatal biogenic XXXX .

@entity9484 @entity6 @entity935 @entity535 @entity3839 @entity4478 @entity750 @entity35
In vivo voltammetry was used to measure the synaptic release of @entity35 striatal @entity935 and @entity750 after the administration of the @entity535 @entity9484 to @entity3839 -induced @entity6 @entity35 . @entity935 and @entity750 release from @entity35 striatum was studied at a short-term or acute (3-day) interval and a long-term or chronic (3- to 7-wk) interval after the induction of @entity6 . The study was also done in age-, sex-, and food-matched controls. The findings show that @entity9484 decreased @entity935 release from @entity35 striatum in nondiabetic @entity35 . The decreased striatal @entity935 release, after @entity9484 administration, was exacerbated in acutely @entity6 @entity35 and further exacerbated in chronically @entity6 @entity35 . By contrast, @entity35 striatal @entity750 release predictably increased after @entity9484 injection in nondiabetic @entity35 . A further increased striatal @entity750 release was seen in acutely @entity6 @entity35 . Chronically @entity6 @entity35 , however, responded to @entity9484 with a dramatic and significant decrease in striatal @entity750 release. The results show that in acutely @entity6 and normal @entity35 , @entity9484 administration reduced striatal @entity935 and increased striatal @entity750 release, whereas in chronically @entity6 @entity35 , the release of both biogenic @entity4478 was decreased. The findings indicate that the progression of @entity6 is associated with an impaired ability to release primary neurotransmitter biogenic @entity4478 .
